EC fines Teva €60.5m over pay-for-delay deal

The European Commission has fined Teva and its subsidiary Cephalon €60.5 million ($72 million) for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Seventh Circuit urged to review AbbVie antitrust ruling

15 October 2020 Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

Big Pharma

AG advises CJEU to uphold €94 million pay-for-delay fine

5 June 2020 The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

Americas

Number of pay-for-delay deals remains low, says FTC

7 December 2020 The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.

More on this story

Big Pharma

Seventh Circuit urged to review AbbVie antitrust ruling

Big Pharma

AG advises CJEU to uphold €94 million pay-for-delay fine

5 June 2020 The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

Americas

Number of pay-for-delay deals remains low, says FTC

More on this story

Big Pharma

Seventh Circuit urged to review AbbVie antitrust ruling

Big Pharma

AG advises CJEU to uphold €94 million pay-for-delay fine

5 June 2020 The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

Americas

Number of pay-for-delay deals remains low, says FTC